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Abstract
Objective
To study blood oxygen level–dependent cerebrovascular reactivity (BOLD-CVR) as a surro-
gate imaging marker for crossed cerebellar diaschisis (CCD).
Methods
Twenty-ﬁve participants with symptomatic unilateral cerebrovascular steno-occlusive disease
underwent a BOLD-CVR and an acetazolamide challenged (15O)-H2O-PET study. CCD and
cerebellar asymmetry index were determined from PET and compared to BOLD-CVR
quantitative values. Neurologic status at admission and outcome after 3 months were de-
termined with NIH Stroke Scale (NIHSS) and modiﬁed Rankin Scale (mRS) scores.
Results
For both the BOLD-CVR and PET examination, a signiﬁcant cerebellar asymmetry index was
found for participants exhibiting CCD (CCD+ vs CCD−: for BOLD-CVR 13.11 ± 9.46 vs 1.52
± 4.97, p < 0.001; and for PET 7.31 ± 2.75 vs 1.68 ± 2.98, p < 0.001). The area under the curve
for BOLD-CVR was 0.89 (95% conﬁdence interval: 0.75–1.0) with 0.91 sensitivity and 0.81
speciﬁcity to detect CCD. Participants exhibiting CCD were in poorer clinical condition at
baseline (CCD+ vs CCD−: NIHSS 7 vs 1, p = 0.003; mRS 3 vs 1, p = 0.001) and after 3-month
follow-up (NIHSS 2 vs 0, p = 0.02; mRS 1 vs 0, p = 0.04). Worse performance on both scores
showed an agreement with a larger BOLD-CVR cerebellar asymmetry index. This was not
found for PET.
Conclusions
BOLD-CVR demonstrates similar sensitivity to detect CCD as compared to (15O)-H2O-PET
in patients with symptomatic unilateral cerebrovascular steno-occlusive disease. Furthermore,
participants exhibiting CCD had a poorer baseline neurologic performance and neurologic
outcome at 3 months.
Classification of evidence
This study provides Class II evidence that BOLD-CVR identiﬁes CCD in patients with
symptomatic unilateral cerebrovascular steno-occlusive disease.
MORE ONLINE
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Crossed cerebellar diaschisis (CCD), known as a func-
tional disconnection of the cerebellar hemisphere con-
tralateral to a supratentorial lesion, is associated with
poor clinical outcome but remains solely a radiologic
diagnosis.1–3 The subsequent reduction in both blood
ﬂow and oxygen extraction fraction in the aﬀected
cerebellar hemisphere is traditionally detected with
(15O)-H2O-PET.
2,4–9 Contemporary MRI techniques,
such as dynamic susceptibility contrast MRI10–12 and ar-
terial spin labeling,13,14 however, may be favored because of
better clinical accessibility and absence of exogenous
radioisotopes.
In this regard, the application of blood oxygen level–
dependent (BOLD) fMRI also deserves further in-
vestigation. From BOLD in combination with a carbon di-
oxide challenge, cerebrovascular reactivity (CVR) can be
quantitatively mapped for the entire brain, including the
cerebellum.15–17 BOLD-CVR is deﬁned as the percentage
BOLD signal change per mm Hg carbon dioxide and is
frequently used to measure supratentorial cerebrovascular
reserve capacity.18 Although BOLD signal changes can
be seen in parallel with changes in cerebral blood ﬂow,19
the BOLD signal primarily depends on changes in
deoxyhemoglobin—not cerebral blood ﬂow changes di-
rectly. In participants with CCD, the presence of hypo-
metabolism in the aﬀected cerebellar hemisphere results in
less oxyhemoglobin being converted to deoxyhemoglobin.
This leads to less deoxyhemoglobin outwash after a physio-
logic cerebral blood ﬂow increase (i.e., preserved cerebral
blood ﬂow reactivity in acetazolamide challenged PET im-
aging) and will subsequently lead to a dampened BOLD
signal increase.20,21
Although a recent study22 has demonstrated good feasibility
of BOLD-CVR for detecting CCD, its diagnostic capacity and
prognostic value remain to be studied in more detail.
Therefore, our aim was to further investigate the role of
BOLD-CVR for CCD.
Methods
Primary research question
Can BOLD-CVR identify CCD in patients with symptomatic
unilateral cerebrovascular steno-occlusive disease?
Classification of evidence
This study provides Class II evidence that BOLD-CVR
identiﬁes CCD in patients with symptomatic unilateral cere-
brovascular steno-occlusive disease.
Standard protocol approvals, registrations,
and patient consents
The research ethics board of the canton Zurich, Switzerland
(KEK-ZH-Nr. 2012-0427), approved the study, and all par-
ticipants signed informed consent before participation.
Participant selection
Twenty-ﬁve participants with symptomatic unilateral cere-
brovascular steno-occlusive disease at either the subacute or
chronic stroke stage were selected from an ongoing pro-
spective BOLD-CVR database between February 2015 and
February 2018. Patients older than 18 years with symptomatic
unilateral cerebrovascular steno-occlusive disease treated at
University Hospital Zurich who gave informed consent were
included in this database. Participants were extracted from
this database and included in the study if they had undergone
acetazolamide challenged (15O)-H2O-PET and BOLD-CVR
imaging within a time frame of 4 weeks. Participants with an
interval more than 4 weeks between PET and BOLD-CVR
imaging were excluded because of potential disease alteration.
All enrolled participants underwent the same PET imaging as
a reference standard. Other exclusion criteria were signs of
cerebellar infarction or other cerebellar pathology on initial or
follow-up imaging, new neurologic symptoms between both
scans, surgical revascularization between both scans and in-
ability or refusal to sign informed consent.
Image acquisition and processing
BOLD-CVR
MRI data were acquired on a 3-tesla Skyra VD13 (Siemens
Healthcare, Erlangen, Germany) with a 32-channel head coil.
BOLD fMRI parameters: axial 2-dimensional single-shot
echo-planar imaging sequence planned on the anterior
commissure–posterior commissure line plus 20° (on a sagittal
image), voxel size 3 × 3 × 3 mm3, acquisition matrix 64 × 64 ×
35 ascending interleaved slice acquisition, slice gap 0.3 mm,
GRAPPA (generalized autocalibrating partially parallel
acquisitions) factor 2 with 32 reference lines, repetition time/
echo time 2,000/30 milliseconds, ﬂip angle 85°, bandwidth
2,368 Hz/Px, and ﬁeld of view 192 × 192 mm2. Two hundred
volumes were acquired for the CVR study. A 3-dimensional,
T1-weighted, magnetization-prepared rapid-acquisition gradi-
ent echo image was also acquired with the same orientation as
the fMRI scans for overlay purposes. Acquisition parameters
were as follows: voxel size 0.8 × 0.8 × 1.0 mm3 with a ﬁeld
of view 230 × 230 × 176 mm and scan matrix of 288 × 288 ×
176, repetition time/echo time/inversion time 2,200/5.14/900
milliseconds, and ﬂip angle 8°. The carbon dioxide stimulus was
given with a computer-controlled gas blender with prospective
gas targeting algorithms (RespirAct; Thornhill Research
Glossary
BOLD = blood oxygen level–dependent;CCD = crossed cerebellar diaschisis;CI = conﬁdence interval;CVR = cerebrovascular
reactivity; MNI = Montreal Neurological Institute; mRS = modiﬁed Rankin Scale; NIHSS = NIH Stroke Scale.
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Institute, Toronto, Canada). This stimulus allows for precise
targeting of arterial partial pressure of oxygen and carbon di-
oxide.15 We controlled the carbon dioxide at the participant’s
own resting carbon dioxide value. During the CVR study,
carbon dioxide was increased approximately 10 mm Hg above
their resting carbon dioxide value for 80 seconds. Oxygen was
maintained at a level of approximately 100 mm Hg during the
entire protocol.
Data preprocessing and BOLD-CVR calculations
All the acquired raw BOLD volumes were transferred and ana-
lyzed with SPM 12 (Statistical Parameter Mapping Software;
Wellcome Department of Imaging Neuroscience, University
College of London, UK). The BOLD volumes were time-
corrected and orthogonalized in 6 translational and rotational
motion estimates to decrease the inﬂuence of head motion. The
BOLD volumes were then aligned to the T1-weighted image and
normalized in Montreal Neurological Institute (MNI) space of
the MNI/ICBM AVG 152 template using a 12-parameter aﬃne
linear transformation andwarping of the images using a nonlinear
transformation. Finally, the BOLD volumes were smoothed with
a gaussian kernel with 8-mm full width at half maximum.
The CVR calculations were done according to a previously
described and validated method.16 In short, after temporal
shifting for optimal physiologic correlation of the 2 time se-
ries, CVR was calculated from the slope of a linear least square
ﬁt of the BOLD signal time course to the carbon dioxide time
series over the range of the ﬁrst baseline of 100 seconds, the
80 seconds step portion of the protocol, and the second
baseline of 100 seconds on a voxel-by-voxel basis. CVR was
deﬁned as the percentage BOLD signal change per mm Hg
carbon dioxide change. The extra BOLD volumes were ac-
quired to allow for potential temporal shift.16
(15O)-H2O-PET study
PET data were acquired on a full-ring PET/CT scanner in
3-dimensional mode (PET/CT Discovery STE; GE Health-
care, Waukesha, WI). The images were corrected for atten-
uation and scatter by using the manufacturer’s own algorithms
and a corresponding CT (120 kV/80 mA). The total axial
ﬁeld of view was 15.3 cm. Images were reconstructed using
a 3-dimensional Fourier rebinning ﬁltered backprojection al-
gorithm giving a 128 × 128 × 47 matrix with 2.34 × 2.34 ×
3.27 mm voxel spacing. Over a period of approximately 20
seconds, 300 to 800 MBq of (15O)-H2O was administered IV
using an automatic injection device. The emission data were
acquired as a series of 18, 10-second frames. Acetazolamide
was injected approximately 13 minutes before the second
PET scan (dose adjusted according to weight) over a period
of 2 minutes. Parametric images of cerebral blood ﬂow before
and after the acetazolamide challenge were generated using
a previously reported method23,24 in which a standardized
arterial input function and image scaling based on the washout
rate k2 of (15O)-H2O are used to determine cerebral blood
ﬂow. This method24 utilizes the fact that k2 is related to the
shape and not the scale of the arterial input function and
proportional to cerebral blood ﬂow. A total count-rate
threshold was set at 50% of the maximum.
The baseline PET image and acetazolamide PET image were
then coregistered to the mean BOLD to allow for normali-
zation of the images. Similar to the BOLD images, normali-
zation of the 2 PET images was done in MNI space and
smoothed with a gaussian kernel with 8-mm full width at half
maximum. CCD was determined visually based on PET
baseline images by an experienced senior staﬀ member of the
Department of Nuclear Medicine (A.B.) who was blinded
toward the BOLD-CVR ﬁndings. For both the PET cerebral
blood ﬂow images and the BOLD-CVR image, a cerebellar
asymmetry index (ipsilateral [to supratentorial stroke] cere-
bellar hemisphere − crossed cerebellar hemisphere/ipsilateral
hemisphere) was determined using a predeﬁned cerebellar
mask to allow for a quantitative analysis of the visually selected
CCD-positive and -negative groups. This cerebellar asym-
metry index is reported as a percentage.
Assessment of neurologic and functional status
The NIH Stroke Scale (NIHSS) and modiﬁed Rankin Scale
(mRS) were used to evaluate the neurologic and functional
status at the time of stroke, and at 3-month follow-up.
Statistical analysis
We performed the statistical analysis using SPSS Statistics 23
(IBM Corp., Armonk, NY). First, normal distribution was
evaluated using the Shapiro-Wilk test. Means of normally
distributed continuous variables from the CCD-positive and
CCD-negative groups were compared by an independent
Student 2-tailed t test, where p < 0.05 was considered statis-
tically signiﬁcant. Variables with nonnormal distribution were
analyzed using the Mann-Whitney U test. All normally dis-
tributed continuous variables are reported as mean ± SD.
Categorical ordinal variables are presented as median (inter-
quartile range) whereas dichotomous variables are shown as
frequency (%). To evaluate cerebral blood ﬂow reactivity in
PET imaging as well as the quantitative intrasubject cerebellar
hemisphere CVR diﬀerences, we used a paired sample t test.
For the assessment of detecting CCD, a receiver operating
characteristic curve and the area under the curve were cal-
culated, including a conﬁdence interval (CI). A Bland-Altman
analysis was used to compare mean diﬀerences in cerebellar
asymmetry index between BOLD-CVR and PET baseline
imaging, and the results were plotted to evaluate the agree-
ment between the 2 techniques and potential bias.
To identify a relationship between the cerebellar asymmetry
index, detected by either BOLD-CVR or one of the PET
images, and neurologic outcome after 3 months, measured
using NIHSS and mRS, we used a Spearman rank-order
correlation analysis.
Data availability
In addition to the detailed methodologic description provided
in this report, numeric data of the individual 27 datasets can
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also be made available in anonymized format. Please contact
the corresponding author for such a request.
Results
From the prospective database, 33 participants underwent both
(15O)-H2O-PET and BOLD-CVR scans resulting in 35 datasets
that were considered for inclusion. After evaluation of exclusion
criteria, 25 participants were eligible for further analysis. Two
participants qualiﬁed for inclusion twice. One participant ful-
ﬁlled the inclusion criteria twice as he experienced 2 ischemic
events on separate occasions, while a second participant un-
derwent pre- and postsurgical imaging after extracranial-to-
intracranial bypass revascularization. Eight patients were
excluded because the time period between PET and BOLD-
CVR scans exceeded 4 weeks and one patient was excluded
because of missed follow-up scans. In total, 27 combined
BOLD-CVR and PET studies were performed in 25 partic-
ipants. Mean age was 57 ± 15 years and 70% of the participants
weremen. The clinical and relevant baseline characteristics of all
participants are shown in tables 1 and 2. Of the 27 datasets, 11
(41%) were classiﬁed as CCD positive. None of the 10 partic-
ipants (11 datasets) with CCD positivity showed clinical signs
of cerebellar dysfunction. Two participants from the CCD-
negative group and one participant from the CCD-positive
group underwent thrombolysis previous to the BOLD and PET
scans. Exemplary imaging illustrations of one CCD-positive and
one CCD-negative participant are shown in ﬁgure 1.
Table 1 Participant characteristics
Participant Age, y Sex Diagnosis (TOAST)
Angiographic
findings
Time from ischemic
event to imaging
1 78 M Carotid atherosclerosis (TOAST 1) L ICA occlusion 79 mo
2 33 F Spontaneous dissection (TOAST 4) L ICA dissection 1 wk
3 44 F Moyamoya disease (TOAST 4) R MCA stenosis 57 mo
4 47 M Carotid atherosclerosis (TOAST 1) L ICA occlusion 21 mo
5 67 F Carotid atherosclerosis (TOAST 1) L ICA stenosis 1 mo
6 81 M Carotid atherosclerosis (TOAST 1) R ICA stenosis 1 and 5 moa
7 65 M Carotid atherosclerosis (TOAST 1) R ICA occlusion 3 wk
8 62 F Intracranial stenosis (TOAST 1) L MCA occlusion 3 wk
9 63 M Moyamoya-like collateral supply (TOAST 4) R MCA stenosis 13 mo
10 63 M Intracranial stenosis (TOAST 1) L MCA stenosis 2 wk
11 76 M Carotid atherosclerosis (TOAST 1) R ICA stenosis 1 mo
12 52 M Carotid atherosclerosis (TOAST 1) L ICA occlusion 10 mo
13 51 F Moyamoya disease (TOAST 4) R MCA stenosis 36 mo
14 59 M Carotid atherosclerosis (TOAST 1) R ICA stenosis 1 mo
15 77 F Carotid atherosclerosis (TOAST 1) L ICA stenosis 1 mo
16 50 M Carotid atherosclerosis (TOAST 1) R ICA stenosis 1 and 6 moa
17 50 F Moyamoya disease (TOAST 4) L MCA stenosis 4 mo
18 65 M Intracranial stenosis (TOAST 1) R MCA occlusion 2 mo
19 48 M Intracranial stenosis (TOAST 1) R MCA occlusion 1 mo
20 45 M Intracranial stenosis (TOAST 1) R MCA stenosis 3 wk
21 70 M Carotid atherosclerosis (TOAST 1) L ICA occlusion 1 wk
22 40 F Moyamoya disease (TOAST 4) R MCA stenosis 21 mo
23 46 M Moyamoya disease (TOAST 4) L MCA stenosis 1 mo
24 52 M Moyamoya disease (TOAST 4) L MCA stenosis 1 mo
25 69 M Carotid atherosclerosis (TOAST 1) R ICA occlusion 1 wk
Abbreviations: ICA = internal carotid artery; MCA = middle cerebral artery; TOAST classification = Trial of ORG 10172 in Acute Stroke Treatment.42
a Participant underwent the imaging protocol twice.
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BOLD-CVR and PET findings
The CVR cerebellar asymmetry index was diﬀerent in CCD-
positive participants compared with CCD-negative partic-
ipants (13.11 ± 9.46 vs 1.52 ± 4.97, p < 0.001). Similar to the
CVR cerebellar asymmetry index, baseline PET cerebellar
asymmetry index was also asymmetrical in the CCD-positive
group as compared with the CCD-negative group (7.31 ± 2.75
vs 1.68 ± 2.98, p < 0.001). The PET cerebellar asymmetry
index did not diﬀer before and after the acetazolamide chal-
lenge (CCD positive: 7.31 ± 2.75 vs 6.93 ± 1.90, p = 0.6; CCD
negative: 1.68 ± 2.98 vs 0.94 ± 2.61, p = 0.3), indicating
preserved cerebral blood ﬂow reactivity. Supratentorial CVR
in CCD-positive participants was more impaired in the ipsi-
lateral hemisphere as compared to the ipsilateral hemisphere
of CCD-negative participants (0.08 ± 0.09 vs 0.16 ± 0.07, p =
0.01). No diﬀerence was seen for the contralateral hemi-
sphere. All BOLD-CVR and PET ﬁndings are shown in
table 3.
The receiver operating characteristic curve and Bland-
Altman analysis are presented in ﬁgure 2. Here, BOLD-CVR
shows an area under the curve of 0.89 (95% CI: 0.75–1.0).
This area under the curve of BOLD-CVR was not diﬀerent
from the PET imaging (area under the curve PET cerebellar
asymmetry index: 0.94, 95% CI: 0.85–1.0). The receiver
operating characteristic curve showed that with a cutoﬀ
point of 6% BOLD-CVR cerebellar asymmetry index, CCD
could be detected with a sensitivity of 0.91 and a speciﬁcity
of 0.81. The cutoﬀ points for PET baseline cerebellar
asymmetry index and PET Diamox cerebellar asymmetry
index were 4.2% and 5.0%, respectively. The Bland-Altman
analysis showed a proportional bias when combining data
of both groups (r2 = 0.7, p < 0.001; ﬁgure 2B). Considering
the data of the CCD-negative participants alone, a good
agreement was found without proportional bias (r2 = 0.30,
p = 0.1; ﬁgure 2C).
Clinical status and outcome assessments
Clinical status and outcome measurements are presented in
table 4 and ﬁgure 3. Diﬀerences between the CCD-positive
and CCD-negative groups were found for both clinical scores
at the time of stroke (CCD+ vs CCD−: mean [interquartile]:
NIHSS 7 [5] vs 1 [2], p = 0.003; mRS 3 [1] vs 1 [2], p =
0.001). This diﬀerence persisted at 3-month follow-up
(NIHSS 2 [5] vs 0 [0], p = 0.02; mRS 1 [2] vs 0 [1], p =
0.04). Of note, both groups showed an improvement of both
scores at 3-month follow-up.
The relationship between the cerebellar asymmetry index,
detected by either BOLD-CVR or one of the PET images, and
neurologic outcome was calculated using the NIHSS and
mRS scores at 3 months. An increasing BOLD-CVR cere-
bellar asymmetry index showed good agreement with worse
performance on both the NIHSS (r = 0.52, p = 0.02) andmRS
(r = 0.56, p = 0.01). Contrarily, the PET cerebellar asymmetry
index measurements did not (baseline PET: NIHSS: r = 0.31,
p = 0.19; mRS: r = 0.32, p = 0.19; acetazolamide PET: NIHSS:
r = 0.28, p = 0.25, mRS: r = 0.15, p = 0.53).
Discussion
The main ﬁnding of our study is that, similar to baseline and
acetazolamide challenged (15O)-H2O-PET, BOLD-CVR can
detect the presence of CCD with high speciﬁcity and sensi-
tivity. Furthermore, the presence of CCD corresponds to
a poorer neurologic status at baseline and at 3-month follow-
up, a ﬁnding in concordance with previous studies.1,2,25 It is of
Table 2 Relevant clinical and baseline characteristics
Total cohort
(n = 27)
CCD-positive
group (n = 11)a
CCD-negative
group (n = 16)a p Value
Age, y 57 ± 15 56 ± 10 60 ± 15 0.43
Sex, male 19 (70) 8 (73) 11 (69) 0.83
Smoking 13 (48) 6 (55) 7 (44) 0.60
Hypertension 18 (67) 7 (64) 11 (69) 0.79
Hypercholesterolemia 10 (37) 5 (45) 5 (31) 0.47
Obesity 5 (19) 1 (9) 4 (25) 0.31
Diabetes 2 (7) 1 (9) 1 (6) 0.79
Mean CO2 baseline, mm Hg 38.1 ± 2.6 38.2 ± 2.6 38.2 ± 2.6 1
Mean CO2 hypercapnia, mm Hg 47.1 ± 2.5 47.5 ± 2.2 46.8 ± 2.7 0.44
Mean CO2 step change, mm Hg 8.8 ± 1.8 9.3 ± 1.6 8.5 ± 1.9 0.29
Abbreviation: CCD = crossed cerebellar diaschisis.
Data represent mean ± SD or n (%).
a One patient in each group underwent the protocol 2 times.
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interest that the cerebellar asymmetry index derived from
BOLD-CVR showed a strong positive correlation to NIHSS
and mRS stroke severity scores at 3 months.
Others have already reported the feasibility of noninvasive
BOLD-CVR as a novel method to study CCD. A recent
feasibility study22 demonstrated that participants with CCD
identiﬁed with arterial spin labeling (i.e., cerebellar hemi-
spheric cerebral blood ﬂow asymmetry) also had signiﬁcantly
reduced cerebellar hemispheric BOLD-CVR as compared to
control participants without cerebral blood ﬂow asymmetry.
BOLD asymmetry was also studied by using a hyperoxic gas
Figure 1 Example of CCD-positive (A) and CCD-negative (B) participant
(A) A 48-year-old man with ischemia in the right middle cerebral artery territory due to a middle cerebral artery occlusion (white x). He presented with left
facial palsy, left-sided hemiparesis, and dysphasia (NIHSS 9/42, mRS 4). On PET and BOLD-CVR imaging, clear signs of supratentorial hemodynamic im-
pairment can be seen in right middle cerebral artery territory (white arrow). In his cerebellum, cerebellar asymmetry can be appreciated contralateral to his
supratentorial lesion with good spatial agreement between both imagingmodalities, i.e., crossed cerebellar diaschisis (white arrow on bottom images). After
3 months, he showed an improvement of his left-sided hemiparesis, facial palsy, and speech (NIHSS 5/42, mRS 2). (B) A 77-year-old man with ischemia in the
left paracentral lobule due to a left internal carotid artery occlusion (white x). He presented with amild sensorimotor paresis of his right leg (NIHSS 2/42, mRS
3), which resolved quickly. The participant did not experience any neurologic symptoms after 3 months (NIHSS 0/42, mRS 0). For both PET imaging as well as
BOLD-CVR, supratentorial hemodynamic impairment can be appreciated on the left side (white arrow), whereas no crossed cerebellar diaschisis is observed.
BOLD = blood oxygen level–dependent; CCD = crossed cerebellar diaschisis; CVR = cerebrovascular reactivity; DWI = diffusion-weighted imaging; FLAIR = fluid-
attenuated inversion recovery; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale.
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challenge to show signiﬁcant asymmetric cerebellar hemi-
spheric BOLD signal changes in a small cohort of participants
with acute large-volume middle cerebral artery strokes.26
Using a novel carbon dioxide application technique27 and
improved BOLD-CVR analysis methods,16 we were able to
generate high-resolution quantitative cerebellar BOLD-CVR
maps. With a cutoﬀ point of BOLD-CVR cerebellar
asymmetry index of 6, CCD was detected with a sensitivity of
0.91 and a speciﬁcity of 0.81.
Significance of CCD detection
Our study found 40.7% of participants with CCD, which is
similar to the incidence reported by others.7,28–30 Our data
conﬁrm that CCD is related to worse neurologic outcome
Table 3 BOLD-CVR and PET findings
Functional measurement
Total cohort
(n = 27)
CCD-positive
group (n = 11)a
CCD-negative
group (n = 16)a p Value
Mean CVR whole brain 0.15 ± 0.06 0.13 ± 0.07 0.17 ± 0.05 0.04b
Mean CVR affected supratentorial hemisphere 0.13 ± 0.08 0.08 ± 0.09 0.16 ± 0.05 0.01b
Mean CVR unaffected supratentorial hemisphere 0.18 ± 0.06 0.16 ± 0.07 0.19 ± 0.06 0.29
CVR CAI (%) 6.24 ± 9.07 13.11 ± 9.46 1.52 ± 4.97 <0.001b
PET CAI (%) baseline 4.0 ± 4.0 7.31 ± 2.75 1.68 ± 2.98 <0.001b
PET CAI (%) acetazolamide 3.4 ± 3.8 6.93 ± 1.90 0.94 ± 2.61 <0.001b
CVR cerebellar affected (ipsilateral) 0.2 ± 0.06 0.20 ± 0.06 0.21 ± 0.05 0.47
CVR cerebellar unaffected (crossed) 0.19 ± 0.06 0.17 ± 0.06 0.21 ± 0.05 0.12
Abbreviations: BOLD = blood oxygen level–dependent; CAI = cerebellar asymmetry index; CCD = crossed cerebellar diaschisis; CVR = cerebrovascular
reactivity, defined as percentage BOLD signal change per mm Hg CO2.
Data represent mean ± SD.
a One patient in each group underwent the protocol 2 times.
b Significant.
Figure 2 Agreement between PET and BOLD-CVR
Receiver operating characteristic curve (A) of BOLD-CVR and PET for the detection of crossed cerebellar diaschisis. Bland-Altman plot of the whole cohort (B)
and for the crossed cerebellar diaschisis–negative cohort alone (C). Note that a proportional bias can be seen when considering data of both groups. For the
crossed cerebellar diaschisis–negative cohort alone (C), a good agreement is found. BOLD = blood oxygen level–dependent; CAI = cerebellar asymmetry
index; CVR = cerebrovascular reactivity.
Neurology.org/N Neurology | Volume , Number  | Month 0, 2018 e7
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
after stroke, as compared to previous studies.1,2,4,25 On the
contrary, others29,31 have shown that the presence of CCD in
the acute phase has no eﬀect on functional outcome. It is
important to mention that correction of hypoperfusion after
acute-stage stroke could shift some participants from CCD
positive to CCD negative.2 Here, with a PET imaging study,
the presence of CCD was assessed at 4 diﬀerent time points
(before thrombolysis, 3 hours, 24 hours, and 14 days later).2
Here, participants who recovered from CCD tended to have
a more favorable outcome.
CCD data interpretation
CCD may be caused by an interruption of cortico-
pontocerebellar ﬁber tracts projecting via pontine nuclei to
the contralateral cerebellar cortex and cerebellar nuclei
thereby leading to a reduced activation of the cortical Purkinje
cells.32,33 Conversely, alterations of the reciprocal cerebello-
thalamocortical tracts may also result in impaired feedback to
the cerebrum, resulting in less input from the cerebrum.
The net result is that CCD manifests itself primarily through
decreased cerebellar blood ﬂow, oxygen extraction fraction, and
cerebral blood volume.22,29 In the aﬀected cerebellar hemi-
sphere, the decreased cerebral blood volume and blood ﬂow
may occur due to a physiologic vasoconstrictive response to
decreasedmetabolic needs without loss of vasodilatory capacity.
Hence, the cerebral blood ﬂow reactivity (i.e., cerebral blood
ﬂow change in response to a vasoactive stimulus) remains
functional.34–36 Our data also showed no diﬀerence in PET
cerebellar asymmetry index before and after the acetazolamide
challenge, thereby conﬁrming a preserved cerebral blood ﬂow
reactivity. With a preserved cerebral blood ﬂow reactivity, the
reduced cerebellar BOLD-CVR response in participants who
are CCD positivemay therefore be explained by the presence of
hypometabolism. As a consequence, there is, on average, less
conversion of oxyhemoglobin into deoxyhemoglobin. Since the
BOLD signal primarily depends on the relative change in
deoxyhemoglobin (i.e., oxy-/deoxyhemoglobin ratio) before
and after a vasoactive stimulus, BOLD-CVR in the crossed
cerebellar hemisphere will be dampened, despite intact cerebral
blood ﬂow reactivity. Of note, the diﬀerent methodology
between BOLD-CVR and PET imaging may explain the
proportional bias. In participants with CCD, the decrease in
cerebellar cerebral blood ﬂow seems not to be in similar pro-
portions as the relative change in metabolism.
Further CCD considerations
Based on our data and further review of the available liter-
ature, we believe that a subdivision of CCD can be proposed.
CCD, in some cases, has the potential to regenerate and
recover.2,37,38 Why CCD resolves in some cases but persists
in others is still an open question. Therefore, the presence of
an overall more severely impaired supratentorial CVR in our
CCD cohort is a potentially very interesting ﬁnding. Since
not only larger infarctions, but on average overall larger
supratentorial hemodynamic impairment is seen in partic-
ipants with CCD,2,29 we postulate that CCD not only occurs
in case of direct damage to the corticopontine cerebellar
ﬁber tracts, but that severe acute or chronic supratentorial
hemodynamic impairment may also induce CCD. It is
known that hemodynamic impairment, in absence of acute
stroke, can alter brain structure and function39,40—for in-
stance, the theory of a “hibernating brain concept” in
patients with chronic stroke.40 This concept postulates the
decrease of cortical excitability and increase in resting motor
threshold, in case of a misery cerebral perfusion (impaired
or negative CVR). Of note, after revascularization, these
participants showed an increase in cortical excitability and
a decrease in motor resting threshold with alleviation of
misery perfusion.40 This would explain why recovery of
CCD is seen in participants with small infarcts after reper-
fusion with thrombolysis2 and CCD is even found in steno-
occlusive disease participants with misery perfusion but
without radiologically deﬁned stroke lesions.41
From our point of view, we believe a pathophysiologic
distinction needs to be made between lesion-induced and
hemodynamic-induced CCD, especially as the current deﬁni-
tion of CCD still requires the presence of a supratentorial lesion.
We will further study this hypothesis in a larger CCD cohort.
Limitations
Our data must be interpreted in the context of the study
design. First, the study cohort was small (i.e., 27 datasets
Table 4 Measurements of functional and neurologic status
Outcome measurements
Total cohort
(n = 27)
CCD-positive
group (n = 11)a
CCD-negative
group (n = 16)a p Value
NHISS during stroke 2 (6) 7 (5) 1 (2) 0.003b
mRS during stroke 2 (2) 3 (1) 1 (2) 0.001b
NHISS 3 mo 0 (2) 2 (5) 0 (0) 0.02b
mRS 3 mo 0 (1) 1 (2) 0 (1) 0.04b
Abbreviations: CCD = crossed cerebellar diaschisis; mRS = modified Rankin Scale; NIHSS = NIH Stroke Scale.
All values are median (interquartile).
a One patient in each group underwent the protocol 2 times.
b Significant.
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from 25 participants), but in concordance with other
CCD studies.1,2,8 Although our study consisted of a uni-
form participant population (i.e., those with unilateral
steno-occlusive disease), the BOLD-CVR study was per-
formed at either the subacute or chronic stroke stage
with a wide range from 1 week to 79 months. Moreover,
we cannot comment on acute stroke ﬁndings in this par-
ticipant group. Similarly, as seen in another recent BOLD-
CVR study,22 the cerebral blood ﬂow asymmetry values
used to deﬁne CCD were based on a region covering a large
portion of the cerebellum. Our ﬁndings show that hypo-
perfusion and decreased BOLD signal are not present
for the whole cerebellar hemisphere (as can be seen in
ﬁgure 1A). A more detailed analysis of cerebellar anatom-
ical and functional areas may therefore be considered in
future work.
Conclusions
The main ﬁnding of our study is that BOLD-CVR dem-
onstrates similar sensitivity to detect CCD as compared
to (15O)-H2O-PET in patients with symptomatic unilat-
eral cerebrovascular steno-occlusive disease. Furthermore,
CCD-positive participants had a poorer baseline neuro-
logic performance and neurologic outcome at 3 months. Of
interest, a larger BOLD-CVR cerebellar asymmetry index
showed good agreement to worse performance on the
NIHSS and mRS scales at 3 months. This agreement was
not found for the PET cerebellar asymmetry index.
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